ETHYOL: profile and news

Ethyol Benefits Cancer Patients Undergoing Radiotherapy Mar 3, 2006
SAO PAOLO, Brazil, March 3 - A systematic review and meta-analysis of Ethyol (amifostine) found that the agent significantly reduced many side effects of ... - MedPage Today,

Drug Improves Radiation Side Effects Mar 1, 2006
...(Ivanhoe Newswire) -- A new study reveals the drug amifostine (Ethyol) may ease common side effects associated with radiation therapy while making the cancer ... - Ivanhoe,

Subcutaneous Amifostine Feasible During Radiotherapy for Head and ... Mar 1, 2006
Amifostine (Ethyol; Essex-Chemie AG, Lucerne, Switzerland) is an organic thiophosphate that protects normal tissues from free radicals produced by radiation ... - Cancerpage.com,

MedImmune Swings to a Loss Feb 2, 2006
The others are the nasal spray flu vaccine, FluMist, which had $21 million in sales last year, and Ethyol, a treatment for certain side effects caused by ... - TheStreet.com

MedImmune slides on weak earnings Feb 2, 2006
Its chemotherapy aid Ethyol saw sales rise 16% to $25 million. Sales of the company's flu vaccine, FluMist, dropped 61% to $8 million. ... - MarketWatch

MedImmune Reports 2005 Financial Results Feb 2, 2006
4Q2004 Total Product Sales $1,221 9% $482 5% Synagis - Total 1,063 13 439 9 Synagis - US 905 9 379 5 Synagis - ROW 158 45 60 43 Ethyol(R) (amifostine) 95 3 25 ... - PR Newswire (press release),

MedImmune posts 4Q loss Feb 2, 2006
...mark worldwide for the first time. Sales of the cancer patient drug Ethyol were also higher. For 2006, MedImmune forecast between ... - Baltimore Sun,

Ethyol® Decreases Xerostomia Without Increasing Recurrences ... Nov 28, 2005
An international randomized trial has determined that Ethyol (amifostine) protects against xerostomia while not affecting long-term outcomes in patients with ... - Cancer Consultants (press release),

Ethyol® Improves Dry Mouth Without Affecting Survival in Head and ... Nov 14, 2005
According to a recent article published in the International Journal of Radiation Oncology, Biology and Physics, the agent Ethyol® (amifostine) protects ... - Cancer Consultants (press release),

Doxil Clinically Beneficial in Kaposi's Sarcoma Nov 8, 2005
In addition to Doxil, the committee will review Genzyme’s Campath, Pfizer’s Celebrex, SkyePharma’s DepoCyt, MedImmune’s Ethyol, Wyeth’s Mylotarg and ... - RxPG NEWS,

Ethyol® Allows Greater Tolerability of Chemotherapy in Head and ... Sep 29, 2005
...have reported that the dose of Taxol® (paclitaxel) given with hyperfractionated radiotherapy can be dose escalated in patients receiving Ethyol (amifostine). ... - Cancer Consultants (press release),

Ethyol® Allows Greater Tolerability of Chemotherapy in Head and ... Sep 27, 2005
According to a recent article published in the journal Cancer, the cytoprotective agent Ethyol® (amifostine) may allow for greater delivery of chemotherapy in ... - Cancer Consultants (press release),

Oncologic Committee To Meet Nov. 8 On Accelerated Approval ... Oct 7, 2005
In its deliberations, the committee will review the status of Phase IV commitments for Johnson & Johnson/Alza’s Doxil, MedImmune’s Ethyol, Seragen’s Ontak ... - FDA Advisory Committee

MedImmune Expands Executive Ranks With Four New Vice Presidents 08 Sep 2005
In his new position, he will be responsible for strategic oversight of the sales and marketing organization for MedImmune's marketed oncology product, Ethyol. ... - PR Newswire (press release),

MedImmune Reports 2005 Second Quarter and Six-Month Financial ... Jul 21, 2005
Worldwide sales of Synagis were $51 million in the 2005 second quarter, while worldwide sales of Ethyol(R) (amifostine) totaled $23 million and Cytogam(R ... - PharmaLive.com (press release)

MedImmune Reports 2005 Second Quarter and Six-Month Financial ... Jul 21, 2005
Worldwide sales of Synagis were $51 million in the 2005 second quarter, while worldwide sales of Ethyol® (amifostine) totaled $23 million and Cytogam ... - Yahoo News (press release)

MedImmune Q2 loss narrows, sales fall Jul 21, 2005
...$43 million. Sales also declined for Ethyol, a product to reduce kidney toxins in patients undergoing cancer treatment. The drug ... - BusinessWeek

MedImmune Affirms Year Outlook Jul 21, 2005
MedImmune also makes CytoGam, which fights infections caused by organ transplants, and Ethyol, which reduces the toxic effects on the kidneys of chemotherapy ... - TheStreet.com

FDA Accused of Dropping the Ball on Post-Marketing Studies of Fast ... Jun 1, 2005
He lists 16 drugs that are awaiting confirmatory post-marketing studies: Alimta, Arimidex, Celebrex, Depocyt, Ethyol, Gleevec, Iressa, Luveris, Mylotarg ... - MedPage Today,

MedImmune Reports Financial Results for First Quarter 2005 Apr 21, 2005
Sales of Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune globulin intravenous (human)) were $23 million and $12 million, respectively, in the ... - PR Newswire

MedImmune earnings top forecasts Apr 22, 2005
Ethyol, which moderates certain side effects of cancer treatments, dropped 4 percent to $23 million compared with the first quarter of 2004. ... - Baltimore Sun

Health Products Research Reports on 2004 Promotional Activities to ... Apr 7, 2005
23rd in 2003 due to its launch of Aloxi(R) * MedImmune placed 20th, the company's first Top 20 ranking, bolstered by activities supporting Ethyol(R) * Purdue ... - PR Newswire

Other information

Indication
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.

Pharmacology
Amifostine is an organic thiophosphate cytoprotective agent indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer and also to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite, believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.

Mechanism Of Action
The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity.

Drug Category
Radiation-Protective Agents; Unclassified Therapeutic Agents (92:00.00); ATC:V03AF05

Brand Names/Synonyms
A5922; Amifostine; Amifostine Ethiofos; Amifostine [Usan:Ban:Inn]; Aminopropylaminoethyl Thiophosphate; Apaetp; CHEMBANK1693; Ethiofos; Ethyol; Gammaphos; SAPEP; WR 2721; WR 2721C

Dosage Forms
POWDER FOR SOLUTION

Absorption
Not Available

Interactions
-->Interactions for Amifostine:

Special consideration should be given to the administration of ETHYOL^® in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.

Chemical IUPAC Name
2-(3-aminopropylamino)ethylsulfanylphosphonicacid

Chemical Formula
C5H15N2O3PS

Half Life
8 minutes

Drug Type
Approved Drug

# Accession No
APRD00021

CAS Registry Number
20537-88-6